Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 3/20 | 0.45 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | THRA | P10827 | 7/20 | 0.38 |
| ▸ | THRB | P10828 | 7/20 | 0.38 |
| ▸ | KLK1 | P06870 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26828022 | 0.88 | TPMT (0.52) | TPMTKMT2AMEN1PLAUTHRA | |
| SCHEMBL5988755 | 0.81 | KMT2A (0.49) | KMT2AMEN1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL9623646 | 0.81 | TPMT (0.55) | TPMTTTRKMT2AMEN1PLAU | |
| SCHEMBL31619991 | 0.75 | GAA (0.44) | TPMTKMT2AMEN1THRATHRB | |
| SCHEMBL28314163 | 0.75 | TPMT (0.49) | TPMTTTRKMT2AMEN1PLAU | |
| SCHEMBL8913807 | 0.74 | PLAU (0.46) | TPMTKMT2AMEN1PLAUL3MBTL1 | |
| SCHEMBL6725404 | 0.71 | TPMT (0.45) | TPMTPLAUTHRATHRBSMN1; SMN2 | |
| SCHEMBL25788119 | 0.71 | PLA2G2A (0.64) | THRATHRBALDH1A1 | |
| SCHEMBL25788122 | 0.71 | PLA2G2A (0.64) | THRATHRBALDH1A1 | |
| SCHEMBL6725846 | 0.71 | PLA2G2A (0.64) | THRATHRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6765021-B2 | ANTIDIABETIC AGENTS | WYETH | 2004-07-20 | — | — | US | disclosed |
| US-20030083341-A1 | 2,3,5-Substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2003-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083341-A1 | 2,3,5-Substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | INSR, GPR119, IRS1 | TPMT 4239/4885TTR 2592/4885KMT2A 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.